Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.245 USD 0.4%
Market Cap: 27.4m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Enlivex Therapeutics Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Cash from Operating Activities
-$17m
CAGR 3-Years
-5%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Cash from Operating Activities
-$2.8m
CAGR 3-Years
15%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Cash from Operating Activities
$41.6m
CAGR 3-Years
67%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Cash from Operating Activities
-$96.1m
CAGR 3-Years
-4%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Cash from Operating Activities
-$8m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Cash from Operating Activities
-â‚Ş23.2m
CAGR 3-Years
14%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
26m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-17m USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Cash from Operating Activities amounts to -17m USD.

What is Enlivex Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-27%

Over the last year, the Cash from Operating Activities growth was 30%. The average annual Cash from Operating Activities growth rates for Enlivex Therapeutics Ltd have been -5% over the past three years , -27% over the past five years .

Back to Top